USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Bayer Pharma Aktiengesellschaft

USPTO PatentsView assignee record - 326 granted patents across 33 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

326

Total patents granted

CPC technology areas

14.9

Avg claims per patent

-16%

5-year filing velocity

The verdict

Bayer holds 326 US patents across 33 technology areas, rank #1,295 of 50,000 tracked assignees.

#1,295
of 50,000 US assignees by volume: Top 9%
by Innovation Score (53.6/100): 14.9
avg claims per patent: -16%
filing velocity, last 5 yrs

Portfolio overview

Bayer Pharma Aktiengesellschaft has been granted 326 US utility patents between 2015 and 2025, placing Bayer Pharma Aktiengesellschaft at rank #1,295 across all assignees tracked by PlainPatent. This portfolio spans 33 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.9 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Bayer Pharma Aktiengesellschaft is one of the more focused assignees in the PatentsView dataset. By volume, Bayer sits between Alpha And Omega Semiconductor, Ltd. (327 patents, rank #1,291) and Ningde Amperex Technology Limited (326 patents, rank #1,299) - the closest US assignees by grant volume. The composite Innovation Score of 53.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 149 grants, compared with 177 in the 2015–2019 window, a -16% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Bayer Pharma Aktiengesellschaft's 14.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 33 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Bayer Pharma Aktiengesellschaft against peers pursuing similar technology classes.

Alpha and Omega S…

327
Brother Industries

327
Medimmune

327
University of Hou…

327
Hangzhou Hikvisio…

326
Klemm + SOHN & KG

326
Littelfuse

326
Ningde Amperex Te…

326
Bayer Pharma Akti… ◀

326

What this shows Bayer holds 326 patents at rank #1,295, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Bayer

By rank, the assignees closest to #1,295 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Bayer's primary technology class.

Bayer's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

54 Top 9% higher than 91% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Bayer Pharma Aktiengesellschaft patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	1.5%
2016	32	9.8%
2017	47	14.4%
2018	44	13.5%
2019	49	15.0%
2020	30	9.2%
2021	37	11.3%
2022	33	10.1%
2023	22	6.7%
2024	20	6.1%
2025	7	2.1%

Which technologies does Bayer Pharma Aktiengesellschaft patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 289

C07D - HETEROCYCLIC COMPOUNDS 246

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 245

C07K - PEPTIDES 23

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 16

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 15

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 14

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 7

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 6

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 6

C07J - STEROIDS 6

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 3

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 3

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 3

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 3

Top 15 of 33 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#1,295

Across all tracked assignees

Innovation Score

53.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Bayer Pharma Aktiengesellschaft hold?

Bayer Pharma Aktiengesellschaft holds 326 US granted patents filed between 2015 and 2025, spanning 33 technology areas.

What is Bayer Pharma Aktiengesellschaft's Innovation Score?

Bayer Pharma Aktiengesellschaft has an Innovation Score of 53.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Bayer Pharma Aktiengesellschaft focus on?

Bayer Pharma Aktiengesellschaft's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 289 patents. The company has filed patents in 33 CPC subclasses total.

Is Bayer Pharma Aktiengesellschaft's patent filing rate increasing or decreasing?

Bayer Pharma Aktiengesellschaft's recent filing velocity is -16% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Bayer Pharma Aktiengesellschaft's patents?

Bayer Pharma Aktiengesellschaft's patents average 14.9 claims each. This falls within the standard range, providing solid legal coverage.

How is the Bayer Pharma Aktiengesellschaft patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Bayer's 326 grants land it in the top 9% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Bayer ranks #1,295 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.